Unlock instant, AI-driven research and patent intelligence for your innovation.

Medicinal composition containing pentoxifyllinum and etodolic acid and application thereof

A technology of pentoxifylline and etodolac, which is applied in the field of medicine, can solve problems such as no treatment drugs, and achieve the effect of facilitating quality control

Active Publication Date: 2012-03-21
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Among the existing drugs for the treatment of arthritis or hemorrhoids, there is no drug with pentoxifylline and etodolac as the main active ingredients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing pentoxifyllinum and etodolic acid and application thereof
  • Medicinal composition containing pentoxifyllinum and etodolic acid and application thereof
  • Medicinal composition containing pentoxifyllinum and etodolic acid and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1 rat adjuvant arthritis model experiment

[0026] experimental method:

[0027] 40 SD rats (about 200 grams) are randomly divided into four groups according to body weight, i.e. model control group, pentoxifylline group (1.5mg / kg), etodolac group (15mg / kg), composition group (containing pentoxifylline Ketoifylline 1.5 mg / kg, etodolac 15 mg / kg) in 4 groups, 10 rats in each group.

[0028] Modeling of 4 groups of rats: intradermally injecting 0.1 mL of Freund's complete adjuvant into the plantar part of the right hind limb of the rats to establish a pathological model of adjuvant arthritis. On the 4th day after modeling, the rats in the pentoxifylline group, the etodolac group and the composition group were intragastrically administered once a day for a total of 21 days.

[0029] Before modeling, before administration, and 21 days after administration, the changes in the plantar circumference of the fixed part of the right hind limb were measured with a thin...

Embodiment 2

[0049] The experiment of embodiment 2 rat croton oil hemorrhoid model

[0050] experimental method:

[0051] 50 SD rats (about 200 grams) were randomly divided into five groups according to body weight, i.e. model control group, pentoxifylline group (containing pentoxifylline 1.0%), etodolac group (containing etodolac 0.5%), Composition group (containing pentoxifylline 1.0%, etodolac 0.5%), Ma Yinglong group, 10 rats in each group. Intrarectal administration to rats two days in advance, twice a day, soaked with 10mg cotton balls, stuffed the cotton balls into the rectum. should be removed). The last administration should be 2 hours after modeling.

[0052] The croton oil mixed liquid used for modeling the inflammatory agent was prepared with 1 part of distilled water, 4 parts of pyridine, 5 parts of ether and 10 parts of 15% croton oil ether solution. Cover the croton oil with 10 mg cotton ball, put the soaked cotton ball into the anus of the rat, and take it out after sta...

Embodiment 3

[0062] Example 3 Experiment of etodolac-induced gastric mucosal injury in rats

[0063] experimental method:

[0064] 50 SD rats (about 200 grams) are randomly divided into five groups according to body weight, i.e. normal control group, etodolac A group (100mg / kg), etodolac B group (200mg / kg), composition A group (containing Pentoxifylline 5.0 mg / kg, etodolac 100 mg / kg) and composition B group (containing pentoxifylline 5.0 mg / kg, etodolac 200 mg / kg) had 10 rats in each group. Five hours after intragastric administration, aseptic operation was performed under ether anesthesia, 2-3 mL of blood was drawn from the heart, anticoagulated with heparin, the plasma was separated, stored at -20°C, and plasma TNF-α activity was detected. The stomach was quickly taken out, cut along the greater curvature, fixed on the platform and photographed, and the maximum diameter (DMAX) of each injury area was measured and integrated on the IBAS image analysis system (Tontron, Germany) as the gas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicaments and particularly relates to a medicinal composition containing pentoxifyllinum and etodolic acid and application thereof. The medicinal composition disclosed by the invention contains two active ingredients, namely, the pentoxifyllinum and the etodolic acid in a ratio of 0.01-10:1, preferably 0.05-2:1. A large number of experiment researches provethat the medicinal composition of the invention has a remarkable effect of treating arthritis and plays a better role in improving a rat hemorrhoids model.

Description

technical field [0001] The invention belongs to the field of medicine and relates to a western medicine composition and its application, in particular to a pharmaceutical composition containing pentoxifylline and etodolac and its application. Background technique [0002] Arthritis refers to arthritic lesions caused by inflammation, infection, trauma or other factors. It will cause joint dysfunction to varying degrees, and the course of the disease is long, lingering and difficult to heal, and the common feature is a chronic inflammatory process of progressive development. The main clinical manifestations are joint pain, joint swelling, joint dysfunction and other symptoms, and it is one of the important causes of disability. According to statistics, there are as many as 355 million arthritis patients in the world, and more than 100 million arthritis patients in my country, and the number is still increasing. Arthritis has seriously affected life, work and study, so the de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/522A61K31/407A61P19/02A61P9/14
Inventor 赵志全王璐璐
Owner LUNAN PHARMA GROUP CORPORATION